Versant Ventures VI GP, L.P.
SEC CIK 1777654 · EDGAR
BoughtSold
Most active insiders at LENZ, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Versant Vantage II GP-GP, LLC | 10% | — | $10.35M |
| 2 | Olsson Shawn | Chief Commercial Off | — | $261.0K |
| 3 | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | $251.4K | — |
| 4 | MCCOLLUM JAMES W | Dir | $239.3K | — |
| 5 | Chevallard Daniel R. | CFO | $114.3K | — |
| 6 | George Jeffrey P. | Dir | $49.9K | — |
Versant Ventures VI GP, L.P. made no open-market trades at LENZ in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-06-20 | 2025-06-18+ | LENZ | LENZ Therapeutics, Inc. | Versant Ventures VI GP, L.P. | 10% | S - Sale | $30.15 | -200.9K | 1.15M | -15% | -$6.06M |
| 2025-06-20 | 2025-06-20 | LENZ | LENZ Therapeutics, Inc. | Versant Ventures VI GP, L.P. | 10% | S - Sale | $30.25 | -133.9K | 1.97M | -6% | -$4.05M | |
| M | 2024-09-13 | 2024-09-11+ | GLUE | Monte Rosa Therapeutics, Inc. | Versant Ventures VI GP, L.P. | 10% | S - Sale | $6.00 | -567.2K | 6.24M | -8% | -$3.40M |
Purchase Sale Sale after option exercise All abbreviations